Market Cap | 39.56M | P/E | - | EPS this Y | -1.80% | Ern Qtrly Grth | - |
Income | -11.57M | Forward P/E | -2.88 | EPS next Y | -80.40% | 50D Avg Chg | -8.00% |
Sales | 477k | PEG | - | EPS past 5Y | - | 200D Avg Chg | 1.00% |
Dividend | N/A | Price/Book | 8.03 | EPS next 5Y | - | 52W High Chg | -25.00% |
Recommedations | 2.50 | Quick Ratio | 0.32 | Shares Outstanding | 26.87M | 52W Low Chg | 78.00% |
Insider Own | 33.84% | ROA | -113.89% | Shares Float | 17.59M | Beta | 1.49 |
Inst Own | 7.71% | ROE | -703.62% | Shares Shorted/Prior | 535.91K/98.28K | Price | 1.96 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 25,955 | Target Price | - |
Oper. Margin | -16,030.77% | Earnings Date | May 8 | Volume | 11,925 | Change | -2.49% |
BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
HC Wainwright & Co. | Buy | Nov 14, 23 |
HC Wainwright & Co. | Buy | Oct 11, 23 |
HC Wainwright & Co. | Buy | Sep 6, 23 |
HC Wainwright & Co. | Buy | Aug 10, 23 |
HC Wainwright & Co. | Buy | Jul 24, 23 |
HC Wainwright & Co. | Buy | Jun 21, 23 |
HC Wainwright & Co. | Buy | May 11, 23 |
HC Wainwright & Co. | Buy | Mar 30, 23 |
Dawson James | Neutral | Nov 11, 22 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
FROST PHILLIP MD ET AL | 10% Owner 10% Owner | Jan 19 | Sell | 0.43 | 129,802 | 55,815 | 1,896,025 | 01/22/24 |
Altman Peter | President and CEO President and CEO | Jan 11 | Buy | 1.87 | 100 | 187 | 353,715 | 04/14/23 |
FROST PHILLIP MD ET AL | 10% Owner 10% Owner | Dec 16 | Buy | 1.68 | 595,238 | 1,000,000 | 2,025,827 | 12/20/22 |